Closed & Collaborative H2 2025: Mergers, acquisitions, partnerships, collaborations, and strategic agreements The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.

#RNA #ADCs #earlyphaseclinicalservices #biosimilars #marketentry #platformlicensing #Radiopharmaceuticals #hospitalAI #CDxpartnerships #genomicsequencing #biomarkerdiscovery #Digitalhealth #biologics #specialtymedicines #precisionmedicine #MandA #licensingagreements
zurl.co/ch3Xg

Stada revives talk of an IPO – if conditions improve Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.

#Stada #IPO #pharmaindustry #generics #OTC #specialtymedicines #rarediseases #chronicdiseases #biosimilars #plaquepsoriasis #psoriaticarthritis #Crohnsdisease #specialtybiosimilars #aflibercept #denosumab #golimumab #tocilizumab #blockbusterdrugs #GLP1agonists #diabetes #obesity
zurl.co/nbsw4

GSK "well positioned" to weather pharma tariffs GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results

#GSK #pharmatariffs #PharmaNews #financialresults #pharmaspecificUStariffrules #UStariffrules #vaccines #specialtymedicines #severeasthmatherapy #shinglesvaccine #RSV #COPD #asthmabiologic #depemokimab #biologics #meningitisvaccine #antibiotics
pharmaphorum.com/news/gsk-wel...